Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Cell-based therapies for intervertebral disc degeneration: Navigating the path from promise to clinical reality

Shi L., Jiang L., Xing T., Liu K., Chen C., Ma P.

Narrative Review on Back Pain, Disc Degeneration, Scar, published in J Orthop Translat (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
J Orthop Translat (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41836583
PMCID
PMC12988531
DOI
10.1016/j.jot.2025.101041
Citations
2

Abstract (original English)

Low back pain (LBP) remains a leading contributor to global health loss, with its disease burden escalating steadily worldwide. Intervertebral disc degeneration (IDD) serves as the primary pathological basis for specific forms of LBP, driven by a multifactorial cascade involving molecular, biochemical and structural alterations. Conventional conservative treatments merely mitigate symptoms without abrogating or reversing the degenerative process, while surgical interventions-though effective for relieving neural compression-fail to regenerate damaged disc tissue and carry inherent risks such as recurrence. In this context, cell-based therapies have emerged as a major focus of regenerative research for IDD, offering unique potential to facilitate tissue repair and ameliorate pain. Nevertheless, substantial hurdles endure: the mechanisms of action remain incompletely defined, standardized cell products are lacking, and robust evidence supporting long-term safety and efficacy is scarce. This review focuses on cell-based therapies for IDD, systematically examines the global research landscape and recent advances, investigates the proposed mechanisms of action, analyzes the current status of clinical research, and outlines future directions, aiming to inform and guide further exploration in this rapidly evolving field. The Translational Potential of this Article : This work systemat

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research